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BloodPAC is a public–private consortium that develops standards 
and best practices, organizes and coordinates research studies 
through its members, and operates a data commons to support 
the liquid biopsy research community. Data from the studies 
it organizes are contributed to the BloodPAC Data Commons. 
BloodPAC developed recommendations for 11 preanalytical 
attributes called the Minimum Technical Data Elements (MTDEs) 
that are recommended for studies that it sponsors and for data 
contributed to the BloodPAC Data Commons.
BACKGROUND
Liquid biopsies are samples of nonsolid 
biospecimens, such as blood, that may be 
used for molecular or cellular analysis. 
These biospecimens offer a number of im-
portant clinical benefits relative to more 
traditionally obtained single-site biopsies. 
First they are safer. Second, they are more 
likely to be representative of molecular al-
terations present from multiple metastatic 
sites. Third, involves the ease of acquisition 
on a repeated basis to monitor disease over 
time with limited patient risk. As a result, 
this mode of sample acquisition and analy-
sis has become a top priority of diagnostic 
and pharmaceutical companies, who are 
looking for translational approaches fo-
cused on the development of liquid biopsy 
biomarkers to guide treatment selection, 
assess treatment efficacy, and understand 
mechanisms of acquired resistance after an 
initial response to therapy.
Additional advantages of a liquid biop-
sy-based testing approach include: speci-
men availability within a routine clinical 
practice setting, the ability to control most, 
if not all, preanalytical steps, and the poten-
tial for short turnaround times to inform 
medical decision making.
One of the principles adopted by the 
BloodPAC members was that not only 
should the consortium be data driven, but 
that it should create a data resource for the 
liquid biopsy community. BloodPAC has 
developed just such a resource called the 
BloodPAC Data Commons, which follows 
the principles that its data be FAIR (findable, 
attributable, interoperable, and reusable).
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An analysis of the data contributed 
by members to the BloodPAC Data 
Commons during late 2016 and early 
2017 played an important role in motivat-
ing the members to initiate the effort to 
develop the minimum technical (prean-
alytical) data elements (MTDEs) for any 
data submitted to the commons. With the 
focus being on standardization of fields, 
BloodPAC undertook the critical task of 
identifying and selecting the MTDEs for 
the preanalytical variables most commonly 
associated with cell-free DNA (cfDNA) 
test design and development.
BloodPAC believes that if it is to suc-
ceed in its mandate, it will need to provide 
all test developers, including translational 
researchers in academia, pharmaceutical 
and diagnostic testing centers, regulators, 
pathologists, and clinicians, with guidance 
regarding factors that influence the perfor-
mance of the assay itself in the laboratory 
that may affect final assay result. These in-
clude defining the factors that may affect 
the limit of detection and the variables 
required to ensure reproducibility/re-
peatability for each phase or aspect of test 
development.
This begins with the definition of pre-
analytical variables and continues to an-
alytical variables and the patient context 
variables that will drive clinical validation.
This paper describes the steps taken 
by the BloodPAC Preanalytical Working 
Group to develop a comprehensive list 
of preanalytical variables relevant to 
cfDNA-based tests. This list was de-
veloped with input from all BloodPAC 
members. By leveraging the strength of 
the diverse BloodPAC membership and 
in collaboration with the US Food and 
Drug Administration’s (FDA’s) Center for 
Devices and Radiological Health (CDRH) 
and the College of American Pathologists’ 
(CAP’s) Preanalytics for Precision 
Medicine Project team, we aligned on a list 
of 11 preanalytical MTDEs. Use of these 
MTDEs by investigators and researchers in 
the field will enable standardization of data 
input into the BloodPAC Data Commons, 
which is necessary to enable cross-assay 
comparisons and other joint analysis of 
its data by its members. We describe the 
process BloodPAC used for selecting pre-
analytical variable MTDEs, along with the 
final list of 11 preanalytical MTDEs, with 
the hope that the research community em-
braces these standards for robust cfDNA 
assay development.
PREANALYTICAL MTDE FOR LIQUID 
BIOPSIES
Version 2.0 of the preanalytical MTDEs 
are listed in Table 1. These MTDEs were 
approved by the BloodPAC Consortium 
on September 26, 2017, received FDA 
input on November 3, 2017, and were 
approved by CAP on June 6, 2018. 
Figure 1 contains a graphical summary of 
the MTDEs.
Fifty-two data elements that are specific 
to cfDNA-based tests were discussed by 
the BloodPAC Consortium, including 26 
preanalytical data elements that are rele-
vant for this paper. The 11 data elements 
in Table 1 were consistently ranked by 
BloodPAC members as “important and re-
quired.” Other categories included “import-
ant and useful,” if the consortium members 
saw these as potentially affecting cfDNA 
assay results, and “useful but not required.” 
This latter category included variables 
that may be useful to collect for rigorous 
research purposes, but that should not be 
required when submitting data to resources 
such as the BloodPAC Data Commons. 
For example, the variable “Temperature of 
Sample During Centrifugation” fell into 
this ranking, since it is important data to 
have when available, but may not be cap-
tured in every data set. Finally, some of the 
data elements were ranked as “not import-
ant and not useful” by members and were 
not considered to be required for data col-
lection or upload.
When selecting the preanalytical MTDEs, 
BloodPAC’s PreAnalytical Working Group 
wanted to balance preanalytical variables 
that could contribute to changes in molec-
ular results and could be readily obtained vs. 
those that might not be readily obtained in a 
real-world setting. The selection process was 
also informed by preanalytical data elements 
contributed by members and the experience 
of those that have led and/or participated 
in preanalytical validation studies profil-
ing molecular and cellular components of 
blood.1
PREANALYTIC STANDARDS FOR 
BIOSPECIMENS
Common preanalytical variable standards 
were established for the handling and 
processing of histopathology samples that 
predated the implementation of molecular 
testing (reviewed in ref. 2). The collection, 
handling, and processing of biospecimens 
have long been recognized to contribute 
to assay variability and challenges of assay 
validation.3–8 In fact, overlooking prean-
alytical variables can have negative conse-
quences for diagnostic development.9
In the context of assay development, the 
preanalytical steps pertain to everything re-
lated to the sample before any assay is run. 
The preanalytical phases include the patient 
phase (whereby variables are difficult to 
control) and the collection phase (whereby 
variables can be more easily controlled). 
Nevertheless, patient-context factors that 
can influence preanalytical variables, such 
as age, gender, comorbidities, medications, 
pregnancy, exercise, and diurnal cycles, are 
becoming more important in the develop-
ment and execution of molecular assays, 
and where possible these variables are being 
factored into the development of newer 
molecular assays. Common preanalytical 
elements include, but are not limited to, 
collection containers, specimen tempera-
ture, sample preparations/stabilizations 
along with time in transit and storage until 
a sample is tested.
In addition, we are seeing examples of 
local coverage determination for cfDNA 
panels offered by single commercial labora-
tories. While these are the early entries into 
Indianapolis, Indiana, USA; 24Novartis Pharmaceuticals, Cambridge, Massachusetts, USA; 25Personal Genome Diagnostics, Baltimore, Maryland, USA; 
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Table 1 A summary of the minimum technical data elements (MTDE)
# Data element Data model element Type Description
1 Blood collection 
tube type




• Acid Citrate Dextrose 
(ACD)
• Not Applicable
The kind of tube used to collect the sample(s) 
taken from a biological entity for testing, 




Composition Controlled vocabulary from:
• Clinical




• Bone Marrow 
Components
• Bone Marrow 
Components NOS
• Control Analyte
• Circulating Tumor Cell 
(CTC)
Sample type describing the cellular composition 
of the sample, as specified from a controlled 




shipping_temperature Float The temperature, in centigrade, at which the 
biospecimen was kept while it was being 





blood_fractionation_method String The name or description of the method used to 
obtain the blood fraction sample. (e.g., Ficoll 
Method, Novartis Protocol #001, 2,000 g 
centrifuge at 4°C with gentle deceleration). 
Alternatively, if you have provided a detailed 
protocol, enter its file_name here.





• or either Unknown or Not 
Applicable
The upper/lower limit on the amount of time, 
in hours, between the blood draw and the 
fractionation into its components. If the exact 
time is known, make this value equal to that 
of the lower limit. If the time is completely 
unknown, enter Unknown. If no fractionation was 
performed on this sample, enter Not Applicable.
6 Analyte isolation 
method
analyte_isolation_method String The name or general description of the method 
used to isolate the analyte. Alternatively, if you 
have provided a protocol, put the file_name 
here.
7 Time to freezer hours_to_freezer_upper, 
hours_to_freezer_lower
• Float
• or either Unknown or Not 
Applicable
The upper/lower limit on the amount of time, in 
hours, that it took between the sample being 
fractionated and the aliquot being frozen or 
otherwise preserved. If the exact time is known, 
make this value equal to that of the lower 
limit. If the time is completely unknown, enter 
Unknown. If no fractionation was performed on 
this sample, enter Not Applicable.
8 Storage 
temperature
storage_temperature Float The temperature, in centigrade, at which the 








Float If the analyte is a molecule (e.g., DNA or RNA), 
report the observed concentration in nanograms 
per microliter (for molecular concentration). 
If the measurement is a cell count, then 
this is reported as cells per microliter 
(cellular_concentration)
10 Assay method assay_method Controlled vocabulary from:
• Targeted Sequencing
• Copy Number Analysis
General name or description of the method used 
to characterize the analyte.
11 Time to assay days_to_assay Integer The amount of time, in days, between the date 
used for index and the assay used to address 
this analyte.
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clinical care, given the logistical and safety 
benefits of blood-based vs. tissue-based 
testing and growing confidence in the abil-
ity for cfDNA tests to have clinically appro-
priate sensitivity and specificity, more tests 
are being developed in Clinical Laboratory 
Improvement Amendments (CLIA)-
approved and CAP-approved laboratory 
settings. As such, undoubtedly, there will 
be an increasing number of tests submitted 
for regulatory approval; such is the case for 
the Guardant 360 assay (Guardant Health, 
Redwood City, CA) and FoundationOne 
Liquid Assay (Foundation Medicine, 
Cambridge, MA), both of which have re-
ceived breakthrough designation status.
BLOODPAC’S PROCESS FOR DEFINING 
MTDE
At the beginning of 2017, the Sample 
Working Group within the larger 
BloodPAC Consortium initiated a col-
laborative and iterative process to identify, 
define, standardize, and prioritize a list of 
variables to be required as annotations to 
each submission of liquid biopsy sample 
data into the BloodPAC Data Commons. 
The initial focus of the Sample Working 
Group’s objective was to identify preana-
lytical variables specifically related to the 
collection and processing of samples for 
cfDNA analysis.
The process of identifying, defining, and 
standardizing key cfDNA preanalytical 
variables began with a review of protocols 
for sample collection and processing that 
were submitted by BloodPAC members at 
the time of the initial deposition of sample 
data into the prototype BloodPAC Data 
Commons at the end of 2016.10 A total of 
nine protocols representative of submis-
sions by diagnostic companies, the pharma-
ceutical industry, and academic institutions 
and that spanned multiple assay platforms 
were reviewed. As a result of this initial 
review, a total of 26 variables relevant to 
cfDNA sample collection, storage, han-
dling, and processing were identified. This 
list of variables was then further reviewed 
by the BloodPAC cochairs and Sample 
Working Group members who refined the 
list to 11 variables that were proposed by 
the cochairs as the preanalytical MTDEs, 
or the minimal descriptive variables re-
quired for the annotation of any data into 
the BloodPAC Data Commons. This list 
of 11 MTDEs was then presented to all 
BloodPAC members at the Q2 2017 meet-
ing held in Boston, Massachusetts in June 
2017. Based on member consensus, this 
list was incorporated into Data Model 2.0, 
and consensus definitions were included 
in the BloodPAC Data Dictionary. See 
Figure S1 in the Supplementary Materials. 
As a result, all new and existing sample data 
submissions were made compliant to the 
inclusion of these 11 MTDEs.
After the consensus list of 11 initial 
preanalytical MTDEs was defined and im-
plemented, the working group continued 
this iterative process of identifying and 
prioritizing relevant cfDNA preanalytical 
variables through an expanded protocols 
review, initial FDA consultation, and ad-
ditional rounds of cochair review. As a re-
sult of this process, the list of data variables 
was expanded to the 52 variables. The 11 
MTDEs identified were included in this 
second round of review based on the co-
chairs’ consensus on their importance. The 
Sample Working Group then continued to 
refine and prioritize the list.
The Sample Working Group’s rankings 
were averaged to assign an importance 
ranking to each of the 52 variables and 
then presented to the entire BloodPAC 
Consortium at the Q3 2017 all-member 
meeting held in New York, New York in 
September 2017.
After the consensus rankings were com-
piled, the prioritized list as well as the iter-
ative process followed to identify MTDEs 
were presented to the FDA at a second con-
sultation meeting held in November 2017. 
As a result of FDA feedback and alignment, 
the 11 MTDEs were finalized as minimally 
important variables to describe preanalyti-
cal conditions relevant to cfDNA analyses. 
Figure S1 in the Supplementary Materials 
contains a summary of this process.
Note that the final MTDEs are designed 
to cover all analytes, not just cfDNA. For this 
reason, during the past 18 months, we have 
updated the names of some of the MTDEs, 
such as "DNA_concentration," which 
Figure 1 A graphical workflow view of the 11 Minimum Technical Data Elements (MTDEs).
VOLUME 107 NUMBER 4 | April 2020 | www.cpt-journal.com734
PERSPECTIVES
was renamed "molecular_concentration" 
in order to cover both molecular and cellu-
lar concentrations.
SUPPORTING INFORMATION
Supplementary information accompanies 
this paper on the Clinical Pharmacology & 
Therapeutics website (www.cpt-journal.com).
Figure S1. The collaborative and iterative 
process that the BloodPAC Sample Working 
Group used to develop the Minimum Technical 
Data Elements (MTDEs).
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